Precision Cancer Medicine thematic member, Dr Yong Wei Peng was part of a team who developed an antibody-drug conjugate (ADC), the first of its kind to be created in Singapore. A collaborative effort between A*STAR’s Bioprocessing Technology Institute and Institute for Molecular and Cell Biology, the Experimental Drug Development Centre, and the National Cancer Centre Singapore, this ADC selectively target cancer cells present across a range of solid tumours.
The first human trials are set to be conducted with patients with solid tumours. It is the first made-in-Singapore drug to receive approval from the U.S. Food and Drug Administration (FDA) to do so.
Read more about this medical milestone here:
